![](https://news.europawire.eu/wp-content/uploads/2016/04/Boehringer-Ingelheim-EU-grants-marketing-authorisation-for-Giotrif®-for-the-treatment-of-patients-with-advanced-squamous-cell-carcinoma-SqCC-of-the-lung-132x150.png)
• Approval provides a new oral treatment option for patients with the second largest sub-type of non-small cell lung cancer (NSCLC), representing approximately 20-30% of NSCLC cases.1,2 • Approval of Giotrif® is based on results of the LUX-Lung 8 study, … Read the full press release